Rapid Genotype Assay for Individualized Warfarin Dosing
Jeffrey Anderson
Douglas Zipes
JEFFREY ANDERSON, University of Utah, Salt Lake City
COMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis
REFERENCE: Abstract 1020-89, American College of Cardiology New Orleans
The hope of refining treatments for cardiovascular disease by genotyping patients to detect individual sensitivities to particular medical therapies was brought a step closer at the ACC meeting in New Orleans by results from a study using a rapid genothype test. Jeffrey Anderson told Peter Goodwin about the assay they’ve been investigating which indicates required dosing of warfarin.
[audio:https://www.audiomedica.com/podcasting/cardio/acc2007/070325_jeffrey_anderson_douglas_zipes.mp3]The hope of refining treatments for cardiovascular disease by genotyping patients to detect individual sensitivities to particular medical therapies was brought a step closer at the ACC meeting in New Orleans by results from a study using a rapid genothype test. Jeffrey Anderson told Peter Goodwin about the assay they’ve been investigating which indicates required dosing of warfarin.
